How These Healthcare Stocks are Performing? -- AMAG Pharma, IDEXX Laboratories, Neogenomics, and ICON

Jul 29, 2016, 08:50 ET from Chelmsford Park SA

NEW YORK, July 29, 2016 /PRNewswire/ --

The Healthcare sector remains one of the most stable industries in the market, unfazed by economic conditions and uncertainties. While the industry faces issues with cost pressures, ransomware risks, and existing policies, several companies remain unscathed and continue to impress with significant returns. Stocks to evaluate today on are AMAG Pharmaceuticals Inc. (NASDAQ: AMAG), IDEXX Laboratories Inc. (NASDAQ: IDXX), Neogenomics Inc. (NASDAQ: NEO), and ICON PLC (NASDAQ: ICLR). Learn more about these stocks by accessing their free notes at:

AMAG Pharma  

Waltham, Massachusetts headquartered AMAG Pharmaceuticals Inc.'s stock finished Thursday's session 1.15% lower at $26.59 with a total volume of 539,046 shares traded. The Company's shares have advanced 14.86% in the past month. The stock is trading 14.72% and 3.01% above its 50-day and 200-day moving averages, respectively. Additionally, shares of AMAG Pharmaceuticals, which provides products and services with a focus on maternal health, anemia management, and cancer supportive care in the U.S., have a Relative Strength Index (RSI) of 60.90.

On July 18th, 2016, AMAG Pharmaceuticals announced that William Heiden, its Chief Executive Officer, has been named to the Board of Directors of the Pharmaceutical Research and Manufacturers of America. Visit us today and access our complete notes on AMAG at:

IDEXX Laboratories  

On Thursday, shares in Westbrook, Maine headquartered IDEXX Laboratories Inc. recorded a trading volume of 598,631 shares. The stock ended the session 0.47% higher at $93.21. The Company's shares have advanced 5.29% in the last one month, 15.37% in the previous three months, and 27.83% since the start of this year. The stock is trading 2.67% above its 50-day moving average and 19.29% above its 200-day moving average. Moreover, shares of IDEXX Laboratories, which together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, water testing, and dairy markets worldwide, have an RSI of 53.53.

On July 20th, 2016, research firm Canaccord Genuity reiterated its 'Buy' rating with an increase of the target price to $98 a share from $90 a share for the Company's stock.

On July 27th, 2016, IDEXX Laboratories announced the availability of Legiolert, the easiest culture method for the confirmed detection of Legionella pneumophila in drinking water. Legiolert improves public health response times by accurately detecting the presence of Legionella pneumophila in potable water systems in seven days, versus up to 14 days with traditional culture methods. The complimentary notes on IDXX can be accessed at:


Shares in Fort Myers, Florida headquartered Neogenomics Inc. closed the day 0.11% higher at $9.12. The stock recorded a trading volume of 249,117 shares. The Company's shares have gained 15.74% in the last month, 15.59% in the previous three months, and 15.88% on an YTD basis. The stock is trading 5.41% above its 50-day moving average and 21.39% above its 200-day moving average. Additionally, shares of Neogenomics, which through its subsidiaries, operates a network of cancer-focused genetic testing laboratories providing genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, and other laboratories in the U.S., have an RSI of 55.59.

On July 26th, 2016, NeoGenomics reported its results for Q2 2016. Consolidated revenue for Q2 was $63.1 million, an increase of 159% over the same period last year.  Clinical genetic test volume grew 158% driven by the inclusion of Clarient's results as well as a 32% y-o-y increase in base NeoGenomics genetic test volume.

On July 27th, 2016, research firm The Benchmark Company reiterated its 'Buy' rating with an increase of the target price to $12 a share from $10 a share for the  stock of Neogenomics. Register for free on and access the latest notes on NEO at:


At the close, shares in Dublin, Ireland headquartered ICON PLC ended at $78.69, gaining 1.03%. The stock recorded a trading volume of 815,226 shares, which was above its three months average volume of 523,980 shares. The Company's shares have advanced 17.52% in the last one month, 17.20% over the previous three months, and 1.27% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 14.02% and 12.06%, respectively. Furthermore, shares of ICON, which provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the U.S., and internationally, have an RSI of 69.85.

On July 26th, 2016, ICON reported its financial results for the second quarter with net revenue growing 5.7% year-on-year to $410.6 million. Net income before non-recurring charges in the quarter increased by 10.4% YOY to $64.7 million, or $1.14 per share, on a diluted basis. Gross business wins in the second quarter were a record $622 million. Get free access to your notes on ICLR at:


Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number:  +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA